Introduction {#sec1}
============

G-protein-coupled receptors (GPCRs) trigger a myriad of cellular functions, including regulation of nervous and immune systems, by activation of intracellular signaling proteins, such as heterotrimeric G-proteins (Gs, Gi/o, Gq proteins).^[@ref1]^ GPCRs constitute the largest superfamily of membrane receptors and have been among the most valuable drug targets because of their close association with many diseases.^[@ref2]^ Recent biological studies unveiled the higher complexity of GPCR signaling, that is, that each subtype induces different signaling pathways and physiological responses.^[@ref3]−[@ref5]^ These involve downstream signaling and/or GPCR-interacting proteins, influenced by the characteristic localizations and expression patterns of various GPCRs.^[@ref6]−[@ref8]^ Also, the huge diversity and structural similarities of GPCR subtypes and their complicated overlapping expression patterns have hampered the deeper understanding of specific GPCR signaling that would be critical for drug design. While conventional pharmacology regulates receptor functions by small organic molecules, insufficient receptor selectivity and cell type specificity of these compounds often prevent interrogation of the biological functions of each GPCR subtype. Illuminating characteristics of individual GPCR subtypes in complex biological environments remains challenging.

A set of toolkits, such as optogenetics^[@ref9]^ and chemogenetics,^[@ref10]−[@ref12]^ for artificial switching of membrane receptor functions now contribute greatly to analyses of many physiological events, including those involved in animal behaviors. Optogenetics, relying on photoactivatable membrane receptors, is valuable for interrogating neural circuits *in vivo*.^[@ref9],[@ref13]^ For example, OptoXR can activate specific G-protein pathways by artificial opsin-receptor chimeras.^[@ref14]^ The most widely used chemogenetic approach, designer receptors exclusively activated by designer drugs (DREADD), enables regulation of cell signaling through G-protein pathway-selective activation by a bioorthogonal pair of a pharmacologically inert agonist and an artificial GPCR with a genetically engineered ligand binding site.^[@ref11],[@ref15]−[@ref19]^ Though powerful for unraveling biological phenomena at the cellular level of resolution, these methods cannot determine in detail the roles of individual subtypes of receptor proteins in their corresponding cell signaling and/or physiological events.

The design of chemical switches and handles on the target proteins is promising to investigate the protein functions, such as caged proteins, chemical rescues, and allosteric regulation with small molecules.^[@ref20]−[@ref29]^ Among them, a pioneering strategy for addressing the functions of membrane receptor proteins is optochemical genetics, developed by Trauner *et al.*, which constructs photoresponsive membrane receptors through covalent modification of engineered receptors possessing a genetically introduced Cys with maleimide--azobenzene--ligand conjugates.^[@ref30]−[@ref32]^ This approach enables control of ligand-gated ion channels (*e.g*., ionotropic glutamate receptors) and class C GPCRs (*e.g*., metabotropic glutamate receptors) with large extracellular clamshell-like ligand binding domains. However, its application to class A GPCRs has been limited.^[@ref33]^ Thus, even though a few chemogenetic tools have emerged, these are not yet adequate for controlling cell signaling associated with class A GPCRs, the largest family of GPCRs encoded in the human genome. Tadross and co-workers recently developed drugs acutely restricted by tethering (DART) pharmacology, a chemogenetic method applicable to *in vivo* study, enabling cell type-specific inactivation of endogenous membrane receptors (AMPA-type glutamate receptor and a muscarinic acetylcholine receptor \[mAChR\]) through covalent immobilization of antagonists/inverse agonists on a HaloTag protein expressed on the cell surface.^[@ref34]^ Furthermore, Hodson and co-workers reported a novel method, termed RECON, for prolonged, reversible activation of the large number of SNAP-tagged class A and B GPCRs with benzylguanine-linked peptide agonists.^[@ref35]^ These findings are promising, but potential concerns remain regarding subtype selectivity and design flexibility. For an investigation of the complex and ubiquitous class A GPCR signaling, the simple and generalized design of the chemical switches and handles reflecting receptor specificity would be highly desirable.

We herein describe a new strategy for selective activation of an engineered GPCR. We modified a class A GPCR, adding a His tag as a tether by mutagenesis. We also prepared a metal complex--agonist conjugate (MAC) for the corresponding GPCR by organic synthesis. The high affinity of the MAC, with assistance from the coordination bond, allowed selective activation of the target GPCR in living cells, a process termed coordination tethering ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). We demonstrated that two class A GPCRs, the β~2~-adrenoceptor (β~2~AR) and mAChR (M1R), were chemogenetically activated in living cells because of the 10--100-fold greater affinity of MAC for the mutated GPCR, relative to that for the wild-type receptor, without loss of natural receptor responses. We also showed that coordination tethering enabled selective activation of the His-tag-fused M1R in primary cultured astrocytes which endogenously express a variety of mAChRs. This method is modular and would be generally applicable to class A GPCRs, thus providing a powerful approach for deciphering characteristics of these receptors, in molecular detail.

![Schematic illustration of coordination tethering. A His~4~ tag was introduced into the N-terminal domain of a class A GPCR as a metal coordination site by genetic engineering. The coordination bond between the His~4~ tag and a Ni--NTA tethered on a metal complex--agonist conjugate (MAC) enables selective activation of the target GPCR by increasing potency of the MAC.](oc-2018-00390v_0001){#fig1}

Results and discussion {#sec2}
======================

Design of His Tag-Fused β~2~-Adrenoceptors and MACs for Coordination Tethering {#sec2.1}
------------------------------------------------------------------------------

We recently reported chemogenetic activation of ionotropic and metabotropic glutamate receptors (ligand-gated ion channel and class C GPCR, respectively), two examples of excitatory neurotransmitter receptors in the central nervous system.^[@ref36]^ Our strategy relied on stabilization of their active conformations by complexation of two genetically incorporated His residues with Pd(bpy) (bpy: 2,2′-bipyridine) in a bidentate coordination bond. This method, though useful, was limited to receptors undergoing a large conformational change of their ligand binding domains during activation. It cannot, however, be applied to class A GPCRs that lack such large domains. The goal of this study was to develop a new approach for artificial modulation of the activities of class A GPCRs, on the basis of a distinct strategy of coordination chemistry. Coordination tethering employs a pair of multi-His sequences (known as a His tag) and a Ni^2+^--nitrilotriacetic acid (Ni--NTA) complex, a widely used tool for protein purification, to increase agonist affinity.^[@ref37],[@ref38]^ The dissociation constant of Ni--NTA and His~6~ tag was reported to be 14 μM.^[@ref39]^ We envisioned that the coordination bond between the His tag incorporated into a target GPCR and the Ni--NTA tethered in MAC would assist agonist binding. This would evoke selective activation of the engineered GPCR by increasing potency of the modified agonist.

β~2~AR was the first model protein chosen for proof-of-principle, because its structure and activation mechanisms have been most intensely investigated, by single-crystal and cryoEM structural analyses, NMR, and site-directed mutagenesis.^[@ref40],[@ref41]^ These previous findings allowed us to select the N-terminal domain as the insertion site for the His~4~ tag. This was because other extracellular loops, ECL1, ECL2, and ECL3, were regarded as essential for ligand binding kinetics and specificity of β~2~AR, as in other class A GPCRs ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a).^[@ref42]^ Nevertheless, a lack of structural information for the N-terminal region in β~2~AR prevented rational design of the engineered β~2~AR. To obtain an appropriate pair of receptor and MAC, we screened a focused small library consisting of the engineered β~2~ARs with the His~4~ tag placed at various positions, along with a few possible MACs. Expression plasmids for the engineered β~2~ARs were constructed with the His~4~ tag inserted at four different positions, between G1.1/Q1.2, F1.9/L1.10, P1.19/D1.20, and R1.27/D1.28. The resulting products were β~2~AR(1.1H4), β~2~AR(1.9H4), β~2~AR(1.19H4), and β~2~AR(1.27H4), respectively, as designated by Ballesteros--Weinstein nomenclature^[@ref43]^ ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a, see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf) for plasmid construction). Additionally, we chemically synthesized three MACs (**MAC(β**~**2**~**AR, O0)**, **MAC(β**~**2**~**AR, O4)**, and **MAC(β**~**2**~**AR, O8)**) ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}b,c, see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf) for details). These had both phenylephrine (PE), an agonist for ARs, and Ni--NTA connected by ethylene glycol linkers of varied lengths (O0, 20 Å; O4, 39 Å; O8, 53 Å; with distances calculated between secondary amine of PE and ternary amine of NTA) ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}b). As shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}c, this modular molecular design would allow for efficient syntheses of a library of MACs for β~2~AR or other GPCRs.

![Design of His~4~ tag-fused β~2~ARs and MACs. (a) Design of His~4~ tag-fused β~2~ARs. Four different β~2~AR mutants with the His~4~ tag were constructed by genetic engineering. The insertion sites were indicated by red triangles. The full sequence of the N-terminal domain of each mutant is shown in [Table S4](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf). (b) Chemical structures of MACs for β~2~AR. (c) Synthetic scheme of **MAC(β**~**2**~**AR, O4)**. **MAC(β**~**2**~**AR, O4)** was prepared by complexation of **control-1** and 1 equiv of NiSO~4~ at room temperature at 30 min, followed by being used for cellular assays without isolation. Since the affinity between the Ni^2+^ ion and NTA is strong at neutral pH (p*K*~a~: 11.54),^[@ref44]^ the free Ni^2+^ ion is negligible under our experimental conditions. Syntheses of other MACs and their control compounds are shown in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf).](oc-2018-00390v_0002){#fig2}

Screening Experiment {#sec2.2}
--------------------

With the focused library of His~4~ tag-fused β~2~ARs and MACs in hand, we set up an efficient screening system based on fluorescence Ca^2+^ imaging with the indicator Fura-2. To assess β~2~AR activity by changes in intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~), we transiently transfected HEK293T cells with plasmids for both β~2~AR and Gα~15~ proteins^[@ref45]^ ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a). For use in screening experiments, six different types of HEK293T cells were prepared harboring a vector plasmid, plasmids of wild-type (WT) β~2~AR, or four β~2~AR mutants. Using a fluorescence microscope, we then monitored \[Ca^2+^\]~i~ changes upon addition of each MAC or control (0.1 μM) in HEPES-buffered saline (HBS). We defined Δratio as the difference between the initial and maximum ratio values and quantitatively evaluated the activity as shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b.

![Chemogenetic activation of His~4~ tag-fused β~2~AR by coordination tethering. (a) Schematic illustration of fluorescence Ca^2+^ imaging. HEK293T cells were transiently transfected with both β~2~AR and Gα~15~ proteins. PLC, phospholipase C; PIP~2~, phosphatidylinositol 4,5-biphosphate; IP~3~, inositol 1,4,5-triphosphate; ER, endoplasmic reticulum. (b) Ca^2+^ responses induced by 0.1 μM (red) **MAC(β**~**2**~**AR, O4)** or (black) **control-1** in HEK293T cells expressing β~2~AR(1.19H4). Δratio was defined as the difference between the maximum and initial ratio values (*n* = 29, 52). (c) The color map shows the averaged Δratio evoked by 10 min of treatment with 0.1 μM MACs or controls for the control vector, WT β~2~AR, and β~2~AR mutants (*n* = 10--52). O0, **MAC(β**~**2**~**AR, O0)**; O4, **MAC(β**~**2**~**AR, O4)**; O8, **MAC(β**~**2**~**AR, O8)**. (d, e) Concentration--response curves of (d) β~2~AR(1.19H4) and (e) WT β~2~AR for (red) **MAC(β**~**2**~**AR, O4)** and (black) **control-1** (*n* = 15--60). (f) Reversible Ca^2+^ responses of β~2~AR(1.19H4) evoked by 0.1 μM **MAC(β**~**2**~**AR, O4)** (*n* = 28). The data represent the mean ± SEM. Reproducibility of all experiments was confirmed at least three times.](oc-2018-00390v_0003){#fig3}

The Δratio values are summarized as a color map in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c, and these data were used to identify two hit pairs, β~2~AR(1.19H4) or β~2~AR(1.27H4) mutants, each paired with **MAC(β**~**2**~**AR, O4)**. HEK293T cells expressing β~2~AR(1.19H4), for instance, showed a significant change in \[Ca^2+^\]~i~ upon addition of 0.1 μM **MAC(β**~**2**~**AR, O4)** (Δratio = 0.48 ± 0.12), while this effect was not observed with **control-1** (Δratio = 0.037 ± 0.007) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b,c, [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). The other hit pair, β~2~AR(1.27H4) and **MAC(β**~**2**~**AR, O4)**, showed a similar increase in Δratio (0.5 ± 0.2 in **MAC(β**~**2**~**AR, O4)** and 0.030 ± 0.006 in **control-1**). In contrast, with WT β~2~AR, there was no change in \[Ca^2+^\]~i~ on treatment with **MAC(β**~**2**~**AR, O4)** or **control-1** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c, second row). These data suggested that the coordination bond between the His~4~ tag and Ni--NTA was essential for activation of β~2~AR(1.19H4) and β~2~AR(1.27H4).

The screening data also showed that the linker length of MAC was crucial for coordination tethering. For the hit β~2~AR(1.19H4) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c, second row from the bottom), a MAC bearing the shortest linker (**MAC(β**~**2**~**AR, O0)**) failed to activate the receptor, presumably because the Ni--NTA moiety could not reach the His~4~ tag on β~2~AR. The MAC with the longest linker (**MAC(β**~**2**~**AR, O8)**), on the other hand, did activate the β~2~AR(1.19H4) but with much lower potency than that of the hit **MAC(β**~**2**~**AR, O4)**. This was related to entropic loss attributable to an excessively long and flexible ethylene glycol linker. More interestingly, the incorporation site of the His~4~ tag was also critical. When the His~4~ tag was inserted at sites more distant to the ligand binding site (that is in 1.1H4 and 1.9H4 mutants), neither the hit **MAC(β**~**2**~**AR, O4)** nor the longer **MAC(β**~**2**~**AR, O8)** could activate the mutant receptors. With β~2~AR(1.27H4), on the other hand, insertion of the His~4~ tag too close to the transmembrane domain may have impaired the natural function of β~2~AR. Therefore, we selected β~2~AR(1.19H4) as the optimal mutant for more detailed analyses.

Detailed Responses of the Hit Pair β~2~AR(1.19H4) and **MAC(β~2~AR, O4)** {#sec2.3}
-------------------------------------------------------------------------

For the optimal pair, β~2~AR(1.19H4) and **MAC(β**~**2**~**AR, O4)**, the concentration dependence of **MAC(β**~**2**~**AR, O4)** on β~2~AR activity was evaluated. In the case of **control-1**, both WT β~2~AR and β~2~AR(1.19H4) had nearly identical concentration-dependent saturation curves, with EC~50~ values of 1.3 and 1.3 μM, respectively ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}d,e, black lines). This indicated that introduction of the His~4~ tag did not impair receptor activity. As expected, the EC~50~ value of **MAC(β**~**2**~**AR, O4)** for β~2~AR(1.19H4) was increased by 93-fold (0.014 μM) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}d, red line). In sharp contrast, the EC~50~ value of **MAC(β**~**2**~**AR, O4)** for WT β~2~AR was barely shifted (0.68 μM) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}e, red line). We also confirmed that **MAC(β**~**2**~**AR, O4)** activated the engineered β~2~AR(1.19H4) repeatedly, at least three consecutive times ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}f).

As a control experiment, we examined the concentration dependence of agonist-induced activation of the β~2~AR(1.19H4) mutant by PE, in the absence and presence of Ni--NTA or Ni^2+^ ion ([Figure S2a,b](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). The dose dependence was not affected by Ni--NTA or Ni^2+^ ion (EC~50~ values: 0.32 μM for without Ni--NTA or Ni^2+^ ion, 0.38 μM for with Ni--NTA, and 0.36 μM for with Ni^2+^ ion) ([Figure S2c](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). Also, the enhanced response of **MAC(β**~**2**~**AR, O4)** was completely inhibited by ICI-118551, an antagonist for β~2~AR ([Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). These results revealed that two points of interaction between β~2~AR and MAC (using the orthosteric (PE) binding sites and the His tag (Ni--NTA) coordination site) were essential for β~2~AR activation by coordination tethering. In addition, we confirmed that no response was detected in the presence of U73122, a PLC inhibitor ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). This indicated that the observed response induced by **MAC(β**~**2**~**AR, O4)** was evoked by activation of the Gα~15~/PLC pathway.

We also confirmed that coordination tethering could activate the endogenous Gs pathway of β~2~AR by monitoring the concentration change of cAMP. In the case of β~2~AR(1.19H4), the EC~50~ value of **MAC(β**~**2**~**AR, O4)** for cAMP production was lower than that of **control-1** by 24-fold (0.011 and 0.26 μM, respectively) ([Figure S5a](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). In contrast, WT β~2~AR showed no prominent difference in the EC~50~ values between **MAC(β**~**2**~**AR, O4)** and **control-1** (0.23 and 0.16 μM, respectively) ([Figure S5b](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)).

We additionally investigated whether the number of His residues in the His tag sequence affected β~2~AR activation, using a mutant (β~2~AR(1.19H8)) bearing eight His residues at the same insertion position as that of the hit His~4~ mutant (β~2~AR(1.19H4), see [Figure S6a](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf) for the mutant design). The EC~50~ value of **MAC(β**~**2**~**AR, O4)** for β~2~AR(1.19H8) was significantly lower than that of **control-1** (0.017 and 1.0 μM, respectively). This indicated that coordination tethering worked well for this receptor, similarly to results with β~2~AR(1.19H4), and that the longer His tag did not impair ligand--receptor binding ([Figure S6b](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). Meanwhile, the EC~50~ was not considerably improved by increasing the number of His residues, suggesting that four His residues were sufficient for **MAC(β**~**2**~**AR, O4)**-induced receptor activation.

Selective Activation of Muscarinic Acetylcholine Receptors {#sec2.4}
----------------------------------------------------------

To validate the general applicability of this strategy, we next examined selective activation of a second class A GPCR. Muscarinic acetylcholine receptors (mAChRs) are widely expressed in the body, such as in the central and peripheral nervous systems, and are mainly involved in cognitive and behavioral processes.^[@ref46],[@ref47]^ Among five subtypes of mAChRs, we selected Gq-coupled M1R as the target and incorporated a His~4~ tag sequence into the M1R at nearly the same site (M1R(1.18H4)) as in the hit β~2~AR(1.19H4) mutant (using Ballesteros--Weinstein nomenclature, see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf) for plasmid construction) ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a). Concurrently, a MAC was designed for mAChRs (**MAC(M1R)** in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b,c) that included iperoxo, the selective agonist for mAChRs, and Ni--NTA connected by a tetra-ethylene glycol linker. On the basis of the crystal structures of M2R and iperoxo,^[@ref48]^ the linker was connected at the terminal ammonium moiety.

![Chemogenetic activation of mAChR, M1R, by coordination tethering. (a) Design of the His~4~ tag-fused M1R, M1R(1.18H4). Red and green letters represent a His~4~ tag and a HA tag, respectively. (b) Chemical structure of **MAC(M1R)**. (c) Synthetic scheme of **MAC(M1R)**. **MAC(M1R)** was prepared by complexation of **control-2** and 1 equiv of NiSO~4~ at room temperature at 30 min, followed by being used for cellular assays without isolation. (d) Ca^2+^ responses evoked by 0.1 μM of (red) **MAC(M1R)** and (black) **control-2** in CHO cells expressing M1R(1.18H4) (*n* = 18). Concentration--response relationships of (e) M1R(1.18H4) and (f) WT M1R on (red) **MAC(M1R)** and (black) **control-2** (*n* = 17--27). The data represent the mean ± SEM. Reproducibility of all experiments was confirmed at least two times.](oc-2018-00390v_0004){#fig4}

The activities of WT M1R and M1R(1.18H4) transiently expressed in CHO cells were evaluated with fluorescence Ca^2+^ imaging, using a protocol similar to that used for β~2~AR screening. The concentration dependence for activating M1R(1.18H4) showed that EC~50~ of **MAC(M1R)**, compared with **control-2**, was decreased by approximately 16-fold (0.14 μM in **MAC(M1R)** and 2.3 μM in **control-2**, [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}d,e). In contrast, WT M1R showed no substantial difference in EC~50~ values for **MAC(M1R)** and **control-2** (3.7 μM in **MAC(M1R)** and 2.4 μM in **control-2**, [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}f). This clearly implied that selective M1R(1.18H4) activation may be achieved with less than 100 nM **MAC(M1R)**, even in the presence of WT M1R. We also found that the EC~50~ value of M1R(1.18H4) for **control-2** was comparable to that of WT M1R. This suggested that the M1R(1.18H4) mutant retained its natural responsiveness. Additionally, the concentration--response of M1R(1.18H4) for iperoxo was unaffected by addition of 1 μM Ni--NTA ([Figure S7](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). Similar to that of the β~2~AR mutant, activation of M1R(1.18H4) by **MAC(M1R)** was completely inhibited by pretreatment with pirenzepine (an M1R-selective antagonist), YM254890 (a Gq GDP/GTP exchange inhibitor), or U73122 (a PLC inhibitor) ([Figures S8--S10](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf), respectively). This demonstrated that coordination tethering indeed relied on interactions at two sites, enabling activation of the Gq/PLC pathway. It is noteworthy that our design strategy for chemogenetic activation was successfully applied to not only β~2~AR, but also mAChR, even though these two receptors have the lowest sequence homology among the aminergic GPCRs.^[@ref49]^ Furthermore, we confirmed the orthogonality of the His-tagged receptor--MAC pairs. As shown in [Figure S11](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf), **MAC(β**~**2**~**AR, O4)** could not activate M1R(1.18H4) at all and *vice versa*.

Application of Coordination Tethering in Primary Cultured Astrocytes {#sec2.5}
--------------------------------------------------------------------

Finally, we applied the pair **MAC(M1R)**/M1R(1.18H4) to a primary cultured cell system ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}a). In cultured cortical astrocytes, there are several endogenous Gq-coupled mAChR signaling pathways involved in DNA syntheses, cell proliferation, and regulation of neuronal and vascular functions through local release of gliotransmitters.^[@ref50],[@ref51]^ We prepared cultured astrocytes transiently transfected, using nucleofection, with M1R(1.18H4), WT M1R, or vector plasmids. Transfection was confirmed by Western blotting (WB) analysis and immunostaining using a human influenza hemagglutinin (HA) tag inserted at the N-termini of the M1Rs ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a). The WB data indicated that both mutant M1R(1.18H4) and WT M1R were successfully expressed in cultured astrocytes ([Figure S12](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). Immunostaining with an anti-HA tag antibody showed strong fluorescence signals on the membrane surface of astrocytes transfected with M1R(1.18H4) or WT M1R plasmids ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}b and [Figure S13a](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). This indicated that these receptors were localized to the plasma membrane of the astrocytes. In contrast, almost no fluorescence was detected on the cell surface of astrocytes transfected with the vector plasmid ([Figure S13b](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)).

![Selective activation of the engineered M1R in primary rat cortical astrocytes. (a) Schematic illustration of selective activation of the His~4~ tag-fused M1R over endogenous mAChRs by coordination tethering. (b) Confocal microscopic images of astrocytes co-transfected with AcGFP (green) and M1R(1.18H4) immunostained by an anti-HA tag antibody (magenta). Nuclei were stained with Hoechst33258 (blue). Scale bar: 20 μm. Ca^2+^ responses evoked by 30 nM (c) **MAC(M1R)** and (d) **control-2** in astrocytes harboring the plasmids of (red) M1R(1.18H4), (blue) WT M1R, or (black) the control vector (*n* = 18). Fura-2 ratiometric images of astrocytes expressing M1R(1.18H4) (e) before and (f) during perfusion of 30 nM **MAC(M1R)**. Red and blue represent high and low Ca^2+^ concentration, respectively. Scale bar: 100 μm. (g) Average Δratio plot evoked by 5 min of treatment of 30 nM **MAC(M1R)** and **control-2** (*n* = 11--23). \*\*\* denote significant differences from the group of M1R(1.18H4)/**MAC(M1R)**/inhibitor(−) (\*\*\*: *P* \< 0.001, one way analysis of variance with Dunnett's *post hoc* test). F(6/117) = 23.05. Concentration--response curves of (h) M1R(1.18H4) and (i) WT M1R on (red) **MAC(M1R)** and (black) **control-2** (*n* = 20--25). The data represent the mean ± SEM. Reproducibility of all experiments was confirmed at least two times.](oc-2018-00390v_0005){#fig5}

As shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}c--g, Ca^2+^ imaging experiments clearly revealed that astrocytes expressing M1R(1.18H4) were activated by **MAC(M1R)** (30 nM), but not by **control-2**. **MAC(M1R)**-induced receptor activation was inhibited by the M1R-selective antagonist, pirenzepine ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}g). In contrast, cells expressing WT M1R or vector did not show Ca^2+^ signals in response to **MAC(M1R)** (30 nM) ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}c,d,g). Detailed **MAC(M1R)** concentration dependences indicated that its EC~50~ value for M1R(1.18H4) was shifted downward by 4-fold when compared with **control-2** (39 nM in MAC and 170 nM in control) ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}h). In contrast, its EC~50~ values of **MAC(M1R)** and **control-2** for WT M1R showed no prominent difference (390 nM in **MAC(M1R)** and 340 nM in **control-2**) ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}i). Therefore, we concluded that selective receptor activation in astrocytes transfected with mutant M1R(1.18H4) was attributed to a coordination bond-assisted affinity shift of **MAC(M1R)**, selective for the engineered M1R(1.18H4). More importantly, our findings indicated that our coordination tethering strategy is applicable to primary cultured astrocytes containing a variety of endogenous mAChRs.

Conclusion {#sec3}
==========

In summary, we have developed coordination tethering, enabling selective activation of His tag-fused class A GPCRs by MAC, a modified ligand, in living mammalian cells, including primary cultured astrocytes. This approach was validated with two different subfamilies of class A GPCRs, using almost identical design principles in engineering the receptors and chemically modifying the corresponding MACs. We confirmed that both MACs showed no toxicity toward mammalian cells ([Figure S14](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). Also of note, coordination tethering can be applied to receptors with native amino acid residues at extracellular coordination sites accessible to Ni--NTA. In our study, while there are 6 Glu, 5 Asp, 6 His, and 2 Met residues distributed on the N-terminal domain and extracellular loops of β~2~AR ([Figure S15](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)), MAC exhibited high selectivity toward the inserted His~4~ tag without interference by these native residues. These results suggested that a coordination tethering approach can be extended, with flexibility, to a wide range of class A GPCRs. Of further importance, His~4~ tag incorporation into the target receptors did not have a detrimental impact on their responses to ligands, a key advantage for investigating natural receptor functions under equivalent conditions. A critical limitation, on the other hand, is that our coordination tethering method is not applicable to orphan receptors with unknown agonists. Recently intensified efforts to deorphanize GPCRs, however, should gradually resolve this shortcoming.^[@ref52]^ Another possible limitation is the lack of switching systems when we apply this coordination tethering to more complex environments where the EC~50~ value of MAC on His-tagged receptors is more close to that on WT receptors. We will attempt to improve coordination tethering by incorporating a switching mechanism such as a binary ON/OFF step like RECON.^[@ref35]^ In addition, it is conceivable that our short His~4~ peptide insertion may be compatible with rapidly developing *in vivo* genome editing techniques (such as the CRISPR-Cas9 system), enabling incorporation of peptide tags (*e.g*., HA tags) into endogenous proteins in a cell-specific manner.^[@ref53],[@ref54]^ We anticipate that the rational combination of our method with these genetic or virus infection techniques would modulate activity of endogenous GPCRs. Thus, we envision that coordination tethering will facilitate deeper understanding and more precise regulation of cell-specific receptor functions in living tissues and/or animals.

Experimental Procedures {#sec4}
=======================

Detailed procedures for organic syntheses, the site-directed mutagenesis, Western blot analyses, and cell viability assay are provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf).

Culture and Transfection of HEK293T, HEK293, and CHO Cells {#sec4.1}
----------------------------------------------------------

HEK293T, HEK293, and CHO cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) for HEK293T and HEK293 cells or DMEM-F12 (Sigma-Aldrich) for CHO cells supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 unit/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B (Gibco) at 37 °C in a humidified atmosphere of 95% air and 5% CO~2~. For β~2~ARs, HEK293T and HEK293 cells were transiently transfected with plasmids (WT β~2~ARs, the β~2~AR mutants, or the control vector) using Lipofectamine2000 (Invitrogen) and Superfect transfection reagent (Qiagen), respectively, in DMEM supplemented with 10% FBS according to the manufacture's instruction. For M1R, CHO cells were transiently transfected with plasmids (WT M1R, the M1R mutants, or the control vector) using Lipofectamine2000 transfection reagent in DMEM-F12 supplemented with 10% FBS according to the manufacture's instruction. The cells were co-transfected with pEGFP-F (Clontech), pmCherry-F,^[@ref36]^ or pDsRed monomer-F (Clontech) as a transfection marker. For Ca^2+^ imaging, the cells were grown for 24--36 h, seeded on glass coverslips (Matsunami) coated with poly-[l]{.smallcaps}-lysine solution (Sigma-Aldrich), and subjected to Ca^2+^ imaging 4--10 h after seeding.

Culture and Transfection of Primary Cultured Rat Cortical Astrocytes {#sec4.2}
--------------------------------------------------------------------

Primary rat cortical astrocytes were obtained from P2 neonatal SD rat pups (both male and female were used) (Japan SLC) according to the protocol reported by Guaza *et al*.^[@ref55]^ The cortexes were dissected and digested by trypsin (Nacalai) at 37 °C for 30 min under humidified atmosphere (95% air and 5% O~2~). After centrifugation, the cells were resuspended in DMEM--GlutaMAX (Gibco) containing 10% FBS and 1% penicillin--streptomycin, gently dissociated by pipetting, and filtered by a cell strainer (100 μm). After cell counting, the cells were seeded into poly-[d]{.smallcaps}-lysine-coated (Sigma-Aldrich) T75 cultured flasks and grown in humidified atmosphere (95% air and 5% O~2~). At 5 DIV, the culture flasks were shaken at 250 rpm for 16 h at 37 °C. After removal of nonadherent cells, the adherent cells were collected by treatment of trypsin--EDTA. The collected astrocytes were transiently transfected with the plasmids of WT M1R, M1R(1.18H4), or the vector plasmid by Nucleofector (Lonza) according to the manufacture's instruction. The cells were co-transfected with AcGFP as a transfection marker. The transfected cells were seeded on poly-[d]{.smallcaps}-lysine-coated glass coverslips (Matsunami), cultured in humidified atmosphere (95% air and 5% O~2~), and subjected to Ca^2+^ imaging 24--48 h after seeding. The purity of astrocytes (\>80%) was verified by immunofluorescent imaging with an anti-GFAP antibody ([Figure S16](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)). All the experimental procedures were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Use Committees of Kyoto University.

Fluorescence Ca^2+^ Imaging {#sec4.3}
---------------------------

The HEK293T, CHO cells, and astrocytes were loaded with 5 μM Fura-2 AM (Dojindo) for 15--30 min in growth medium, respectively. Fura-2 fluorescence was measured in HBS (107 mM NaCl, 6 mM KCl, 1.2 mM MgSO~4~, 11.5 mM glucose, 0.2 mM CaCl~2~, and 20 mM HEPES at pH 7.4), respectively. Control compounds for β~2~AR and M1R were dissolved in a mixture of HEPES buffer (10 mM, pH 7.4) and DMSO, and D~2~O, respectively. Precursor control compounds (**control-1**, **control-2**, **control-3**, and **control-4**) and 1 equiv of NiSO~4~ were mixed 20--30 min before fluorescence Ca^2+^ imaging. U73122 (Cayman Chemical), YM254890 (Wako), ICI-118551 (Sigma-Aldrich), and pirenzepine (Sigma-Aldrich) were dissolved in HBS from 1000× DMSO stocks. (*R*)-Phenylephrine (TCI) and iperoxo were dissolved in HBS from 1000× H~2~O stocks. Fluorescence images were obtained using a fluorescence microscopy (IX71, Olympus) instrument equipped with a CMOS camera (ORCA-flash 4.0, Hamamatsu Photonics) under xenon lamp illumination, and analyzed with a video imaging system (AQUACOSMOS, Hamamatsu Photonics) according to the manufacture's protocol. The ratio of 340:380 nm fluorescence was determined from the images, on a pixel-by-pixel basis. For facilitation of the screening assay in HEK293T cells ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c and [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf)), two different cell lines expressing one of the constructs were cocultured on a glass coverslip. Each mutant can be distinguished by co-transfected fluorescent proteins having distinct colors as a marker, and the agonist responses of two different mutants were simultaneously assayed.

cAMP Assay {#sec4.4}
----------

A cAMP assay was conducted by using the cyclic AMP select ELISA kit (Cayman Chemical). The transfected HEK293 cells were seeded on cultured dishes and incubated for 2 days in growth medium at 37 °C in a humidified atmosphere of 95% air and 5% CO~2~. The cultured medium was replaced into serum-free DMEM supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 unit/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B, and the cells were incubated at 37 °C for 60 min (serum-starvation). After removal of DMEM, HBS solutions containing agonists and a phosphodiesterase inhibitor (200 μM IBMX (Nacalai tesque)) were added to the cells followed by incubation at 37 °C for 15 min. After HBS solutions were removed, 0.1 M HCl solution was added to the cells, and incubated at room temperature for 20 min. The resultant cells were collected by cell scrapers and homogenized by pipetting. The homogenized solutions were analyzed by the cyclic AMP select ELISA kit (Cayman Chemical) according to the manufacture's instruction.

Immunostaining of Cultured Astrocytes {#sec4.5}
-------------------------------------

Astrocytes cultured on glass coverslips (5 DIV) were fixed with 4% paraformaldehyde at room temperature (rt) for 30 min and washed with PBS buffer. For immunostaining by an anti-GFAP antibody, this was followed by permeabilization with PBS containing 0.1% triton X-100 at rt for 15 min. The cells were blocked with PBS containing 10% normal goat serum for 1 h at rt. After blocking, primary antibodies in PBS buffer containing 1% BSA were added and incubated overnight at 4 °C. Secondary antibodies in PBS buffer containing 1% normal goat serum were added and incubated at rt for 1 h. Used primary antibodies were as follows: mouse anti-GFAP antibody (CST, 3670, ×300) and rabbit anti-HA tag antibody (abcam, ab9110, ×300). Used secondary antibodies were as follows: goat anti-mouse-IgG-Alexa633 antibody (Invitrogen, A21050, ×1000) and goat anti-rabbit-IgG-Alexa633 antibody (Invitrogen, A21070, ×1000). The cells were also stained with Hoechst33258 (Dojindo, 1 mg/mL, ×1000). Cell imaging was performed with confocal microscopy (LSM800, Axio Observer.Z1, ZEISS) equipped with a 63×, numerical aperture (NA) 1.40 oil objective. Fluorescence images were acquired using 405, 488, and 640 nm lines of semiconductor lasers for excitation of Hoechst33258, AcGFP, and Alexa633, respectively.

Statistical Analysis {#sec4.6}
--------------------

Comparison of two groups was made by two-sided unpaired Welch's *t*-test. *Post hoc* multiple comparisons were conducted by using one-way ANOVA and Dunnett's test. Difference with *P* \< 0.05 was considered significant. All statistical analyses were conducted with Kaleidagraph 4.5 software (Synergy Software). All the measurements were taken from distinct samples. The exact *n* values used to calculate the statistics are summarized in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acscentsci.8b00390](http://pubs.acs.org/doi/abs/10.1021/acscentsci.8b00390).Experimental details, plasmid construction, organic syntheses, and additional tables and figures including screening assay results, concentration--response curves, inhibitory effects, cAMP assay results, orthogonality data, Western blotting analyses, immunostaining images, and cell viability assay results ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.8b00390/suppl_file/oc8b00390_si_001.pdf))
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